Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 7.17 USD 2.28% Market Closed
Market Cap: 1.2B USD

Wall Street
Price Targets

XERS Price Targets Summary
Xeris Biopharma Holdings Inc

Wall Street analysts forecast XERS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XERS is 11.73 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.

Lowest
Price Target
8.08 USD
13% Upside
Average
Price Target
11.73 USD
64% Upside
Highest
Price Target
18.9 USD
164% Upside
Xeris Biopharma Holdings Inc Competitors:
Price Targets
002001
Zhejiang Nhu Co Ltd
26% Upside
LLY
Eli Lilly and Co
1% Upside
2096
Simcere Pharmaceutical Group Ltd
27% Upside
033270
Korea United Pharm Inc
50% Upside
2M7C
China Medical System Holdings Ltd
28% Upside
002294
Shenzhen Salubris Pharmaceuticals Co Ltd
16% Downside
600196
Shanghai Fosun Pharmaceutical Group Co Ltd
36% Upside
ZTS
Zoetis Inc
41% Upside

Revenue
Forecast

Revenue Estimate
Xeris Biopharma Holdings Inc

For the last 7 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 100%. The projected CAGR for the next 4 years is 26%.

100%
Past Growth
26%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Xeris Biopharma Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Xeris Biopharma Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XERS's stock price target?
Price Target
11.73 USD

According to Wall Street analysts, the average 1-year price target for XERS is 11.73 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.

What is Xeris Biopharma Holdings Inc's Revenue forecast?
Projected CAGR
26%

For the last 7 years the compound annual growth rate for Xeris Biopharma Holdings Inc's revenue is 100%. The projected CAGR for the next 4 years is 26%.

Back to Top